The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia

Clinical Lipidology

Volumn 9, Issue 5, 2014, Pages 487-503

  McGowan, Mary P ^a,b   Moriarty, Patrick M ^c   Backes, James M ^c  

^a GENZYME CORPORATION   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

antisense oligonucleotide; apoB; cardiovascular disease; homozygous familial hypercholesterolemia; LDL cholesterol; LDL receptor; lipoprotein(a); mRNA

Indexed keywords

ANACETRAPIB; EVOLOCUMAB; EZETIMIBE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MIPOMERSEN; PLACEBO; SIMVASTATIN;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BINDING AFFINITY; CHILL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FATTY LIVER; FEVER; FLATULENCE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LIVER DISEASE; LOW DRUG DOSE; MALAISE; MYALGIA; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SINGLE DRUG DOSE; STOMACH DISTENSION; TREATMENT DURATION; VOMITING;

EID: 84914149139     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.14.43     Document Type: Article

References (55)

1. Rader DJ, Kastelein J J. Lomitapide and mipomersen: two frst-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9), 1022-1032 (2014).
2. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein (a) in homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20, 522-528 (2000).
3. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60(8), 716-721 (2012).
4. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Basis of Inherited Disease (8th Edition). Scriver CR, Beaud AL, Sly WS, Valle D (Eds.), McGraw-Hill, NY, USA, 2863-2913 (2001).
5. Sjouke B, Kusters DM, Kindt I et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J. (2014) (Epub ahead of print).
6. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. National Lipid Association Expert Panel on Familial Hypercholesterolemia: familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S9-S17 (2011).
7. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur. Heart J. 34, 3478-3490 (2013).
8. Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202-2207 (2011).
9. Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D. Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey. Clinicoecon. Outcomes Res. 5, 189-192 (2013).
10. Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J. Clin. Lipidol. 8(1), 18-28. (2014).
11. Khachadurian AK, Uthman SM. Experiences with homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr. Metab. 15, 132 (1973).
12. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J. Am. Col. Cardiol. doi:10.1016/j.jacc.2013.11.002. (2013) (Epub ahead of print).
13. American Academy of Pediatrics. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Natl Heart Lung Blood Inst. NIH Publication No 12, 7486A (2012). www.nhlbi.nih.gov/fles/docs/peds-guidelines-sum.pdf
14. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemia: recommendations for the National Lipid Association Expert Panel of Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S30-S37 (2011).
15. Thompson GR. Heart-UK LDL Apheresis Working Group: recommendations for the use of LDL apheresis. Atherosclerosis 198, 247-255 (2008).
16. Moghadasian MH, Frolich JJ, Saleem M et al. Surgical management of dyslipidemia: clinical and experimental evidence. J. Invest. Surg. 14, 71-78 (2001).
17. Lopez-Santamaria M, Migliazza L, Gamez M et al. Liver transplantation in patients with homozygous familial hypercholesterolemia previously treated by end-to-side portacaval shunt and ileal bypass. J. Pediatr. Surg. 35, 630-633 (2000).
18. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am. J. Cardiovasc. Drugs 13(4), 285-296 (2013).
19. Cuchel M, Meagher EA, duToit Theron H et al. Effcacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, Phase 3 st udy. Lancet 381, 40-46 (2013).
20. Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007).
21. Lomitapide, Sponsor Background Package. US FDA. New Drug Application #203858 Aegerion (2012). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM323843.pdf
22. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113-2120 (2013).
23. Zamecnik PC. Inhibition of Rous sarcoma virus replication and cell transformation by a specifc oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75(1), 280-284 (1978).
24. Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol. Rev. 20, 90-95 (2012).
25. Aboul-Fadl T. Antisense oligonucleotides: the state of the art. Curr. Med. Chem. 12(19), 2193-214 (2005).
26. Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin. Lipidol. 6(6), 675-692 (2011).
27. Agrawal S, Jiang Z, Zhao Q et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl Acad. Sci. USA, 94(6) 2620-2625 (1997).
28. Crooke ST & Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76(2), 269-276 (2013).
29. Yu RZ, Lemonidis KM, Graham MJ et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein b-100. Biochem. Pharmcol. 77, 910-919 (2009).
30. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid. Res. 46(5), 872-884 (2005).
31. Mullick AE, Fu W, Graham MJ et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-defcient mice. J. Lipid. Res. 52(5), 885-896 (2011).
32. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35(3), 460-468 (2007).
33. Yu RZ, Geary RS, Flaim JD et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modifed antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48(1), 39-50 (2009).
34. Li Z, Hard ML, Grundy JS, Singh T, von Moltke LL, Boltje I. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J. Cardiovasc. Pharmacol.64(2), 164-171 (2014).
35. Kastelein JJ, We del MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
36. Akdim F, Tribble DL, Flaim JD et al. Effcacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur. Heart. J. 32(21), 2650-2659 (2011).
37. Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105, 1413-1419 (2010a).
38. Akdim F, Stroes ES, Sijbrands EJ et al. Effcacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611-1618 (2010b).
39. Visser ME, Akdim F, Tribble DL et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid. Res. 51(5), 1057-1062 (2010).
40. Visser ME, Wagener G, Baker BF et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 33(9), 1142-1149 (2012).
41. Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
42. Stein EA, Dufour R, Gagne C et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess effcacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19), 2283-2292 (2012).
43. McGowan MP, Tardif JC, Ceska R et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLOS ONE 7 (11), e49006 (2012).
44. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson, M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 62(23), 24-30 (2013).
45. Santos RD, Duell PB, East C et al. Long-term effcacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. (2013) (Epub ahead of print).
46. Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr. Opin. Lipidol. 23(2), 133-140 (2012).
47. Nordestgaard BG, Chapman MJ, Ray K et al. For the European Atherosclerosis Society Consensus Panel: lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844-2853 (2010).
48. Davidson MH, Ballantyne CM, Jacobson TA et al. Clinical utility of infammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol. 5(5), 338-367 (2011).
49. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS guidelines for the management of dyslipidemias: the Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart. J. 32 (14), 1769-1818 (2011).
50. US Department of Health and Human Services, US FDA. Guidance for Industry. Drug-induced Liver Injury: premarketing clinical evaluation. (2009). www.fda.gov/downloads/Drugs/Guidances/UCM174090.pdf.
51. Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management. J. Inherit. Metab. Dis. 37, 333-339 (2014).
52. Visser ME, Lammers NM, Nederveen AJ et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 54, 2113-2121 (2011).
53. KYNAMRO (mipomersen sodium). Injection solution for subcutaneous injection. Full prescribing information. January 2013. Genzyme Corporation, a Sanof Company (MA, USA). www.kynamro.com/~/media/Kynamro/Files/KYNAMRO-PI.pdf.
54. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350 (2010).
55. Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343, d6891 (2011).